CHE

Custom Home Exteriors, LLC, and CHE Commercial, LLC Unveil New Ownership Structure with CEO Frank Wiesner

Retrieved on: 
Tuesday, March 12, 2024
Culture, CHE, Growth, Management

RALEIGH, N.C., March 12, 2024 /PRNewswire/ -- Custom Home Exteriors, LLC, and CHE Commercial, LLC (The CHE Companies), a construction company specializing in superior exterior siding and roofing solutions, announced a strategic shift in its ownership structure. Founder Stephen Scoggins, while stepping back from day-to-day operations, remains an integral ownership partner in The CHE Companies. Scoggins is now joined by equity partners: Jeremy Boyd, Chief Operating Officer; Scott Burrell, Executive Vice President of Construction; Josh Menold, Chief Financial Officer; and newly appointed addition Chief Executive Officer Frank Wiesner.

Key Points: 
  • RALEIGH, N.C., March 12, 2024 /PRNewswire/ -- Custom Home Exteriors, LLC, and CHE Commercial, LLC (The CHE Companies), a construction company specializing in superior exterior siding and roofing solutions, announced a strategic shift in its ownership structure.
  • Founder Stephen Scoggins, while stepping back from day-to-day operations, remains an integral ownership partner in The CHE Companies.
  • Scoggins is now joined by equity partners: Jeremy Boyd, Chief Operating Officer; Scott Burrell, Executive Vice President of Construction; Josh Menold, Chief Financial Officer; and newly appointed addition Chief Executive Officer Frank Wiesner.
  • The newly structured leadership team brings over 100 years of industry and management expertise to the future of CHE.

LEO Pharma Unveils Late-Breaking Data for Landmark DELTA 3 Open-Label Extension Trial at the 2024 AAD Annual Meeting

Retrieved on: 
Saturday, March 9, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Janus, Medicine, AAD, Safety, JAK, COVID-19, Abstract, Patient, CHE, Congress, Disease, LEO, Leo Pharma, American Academy, Pharmaceutical industry

For DELTA 3, subjects who completed the 16-week treatment period in one of the parent trials DELTA 1 and DELTA 2 were treated with twice daily delgocitinib cream as needed to control their chronic hand eczema for 36 weeks.

Key Points: 
  • For DELTA 3, subjects who completed the 16-week treatment period in one of the parent trials DELTA 1 and DELTA 2 were treated with twice daily delgocitinib cream as needed to control their chronic hand eczema for 36 weeks.
  • “Having the opportunity to present the DELTA 3 findings for the first time at AAD is a chance to prove our complete dedication to addressing the immense burden of this disease.
  • By continuing to share our key data at major dermatology congresses, we hope to drive forward the clinical development of delgocitinib cream as a potential new treatment option.”
    Key secondary endpoints demonstrated an efficacy profile consistent with DELTA 1 and 2 parent trials.
  • Alongside the presentation, new data sets at AAD were shared as e-posters from the preceding DELTA 1 and 2 trials regarding safety, efficacy and systemic exposure.2,3,4

LEO Pharma to Maintain Leadership Role at AAD in 2024 with New Late-Breaking Data Spanning Multiple Therapeutic Areas

Retrieved on: 
Wednesday, March 6, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Adolescence, EVP, American Academy of Dermatology, Ichthyosis, Atopic dermatitis, Pain, Dermatology, Calendar, Annual general meeting, AAD, Safety, Pharmacokinetics, Abstract, CHE, Congress, LEO, ASCEND, Leo Pharma, American Academy, Pharmaceutical industry

LEO Pharma A/S, a global leader in medical dermatology, will present a breadth of new data on moderate-to-severe chronic hand eczema (CHE), congenital ichthyosis (CI) and atopic dermatitis (AD) at the upcoming 82nd American Academy of Dermatology (AAD) Annual Meeting.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, will present a breadth of new data on moderate-to-severe chronic hand eczema (CHE), congenital ichthyosis (CI) and atopic dermatitis (AD) at the upcoming 82nd American Academy of Dermatology (AAD) Annual Meeting.
  • The event is being held from March 8th to 12th in San Diego, California.
  • “Our growing body of clinical evidence reinforces our passion and commitment to advancing the standard of care in medical dermatology,” said Kreesten Meldgaard Madsen, LEO Pharma’s Chief Development Officer.
  • I am proud that we can follow up on our 2023 AAD program with this level of critical data,” said Brian Hilberdink, EVP and President, Region North America, LEO Pharma.

LEO Pharma Announces Positive Phase 3 Head-to-head Data Results from DELTA FORCE Trial Comparing Delgocitinib Cream With Alitretinoin Capsules in Adults With Severe Chronic Hand Eczema (CHE)

Retrieved on: 
Wednesday, January 24, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, IGA, Hope, Delgocitinib, Patient, DLQI, CHE, Alitretinoin, Aes, Safety, Dermatology Life Quality Index, LEO, Leo Pharma, Quality of life (healthcare), Pharmaceutical industry

LEO Pharma A/S, a global leader in medical dermatology, today announced positive results from the DELTA FORCE trial.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced positive results from the DELTA FORCE trial.
  • Delgocitinib cream achieved the primary outcome measure of the trial by demonstrating a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules.
  • Furthermore, patients receiving delgocitinib cream had a lower number of treatment-emergent adverse events (AEs) compared to those receiving alitretinoin capsules.
  • Detailed results from DELTA FORCE are planned to be submitted for scientific presentation and publication at a later date.

LEO Pharma Presents Data at 2024 Winter Clinical and Maui Derm Conferences

Retrieved on: 
Friday, January 12, 2024
Pharmaceutical, Health, Clinical Trials, Ageing, Itch, Patient, DLQI, Sleep, CHE, Disease, Conference, Safety, Dermatology Life Quality Index, Atopic dermatitis, LEO, Leo Pharma, Catalog, Pharmaceutical industry

LEO Pharma A/S, a global leader in medical dermatology, will present a catalog of investigational delgocitinib cream and Adbry® data across 10 posters at the upcoming Winter Clinical and Maui Derm conferences this month.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, will present a catalog of investigational delgocitinib cream and Adbry® data across 10 posters at the upcoming Winter Clinical and Maui Derm conferences this month.
  • The 2024 Winter Clinical Conference will take place Jan. 12-17 in Honolulu, Hawaii, while Maui Derm is being held from Jan. 22-26 in Maui, Hawaii.
  • LEO Pharma is currently developing delgocitinib cream for the treatment of moderate-to-severe chronic hand eczema (CHE) in adults.
  • Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials.

LEO Pharma Announces Positive Outcome of DELTA 3 Open-Label Extension Trial of Delgocitinib Cream in the Treatment of Adults With Moderate to Severe Chronic Hand Eczema (CHE)

Retrieved on: 
Monday, October 30, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Janus, Patient, Quality of life, Leo Pharma, Safety, CHE, LEO, JAK, DELTA, Pharmaceutical industry, Silviculture

LEO Pharma A/S, a global leader in medical dermatology, today announced the positive outcome of the DELTA 3 trial.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced the positive outcome of the DELTA 3 trial.
  • DELTA 3 is a phase 3, single-arm, open-label extension trial of delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
  • All DELTA 3 trial subjects had completed the DELTA 1 or DELTA 2 trials and were offered to immediately enroll into this extension trial.
  • Furthermore, patients who entered the DELTA 3 trial after receiving cream vehicle in the DELTA 1 and DELTA 2 trials reached similar levels of treatment success as the patients previously treated with delgocitinib cream.

Top 2024 Food and Beverage Trends Revealed by Specialty Food Association Trendspotter Panel

Retrieved on: 
Tuesday, October 17, 2023
Food, Health, Climate change, Cirkus, Family, SFA, Seafood, Restaurant, Shanta Shelke, Culture, Show, Taste, Snack, Sesame, Condiment, Specialty Food Association, Drexel University, CRC, Tahini, Penn District, Pennsylvania, CFS, Growth, Drink, Foresight, Friends, Sur La Table, Global Food Safety Initiative, Relaxation, CHE, Research, Carbon footprint, Retail, Soft drink, Aquaculture, Fast food, Mintel

NEW YORK, Oct. 17, 2023 /PRNewswire/ -- The Specialty Food Association (SFA) Trendspotter Panel has predicted what will be hot in specialty food for 2024.

Key Points: 
  • NEW YORK, Oct. 17, 2023 /PRNewswire/ -- The Specialty Food Association (SFA) Trendspotter Panel has predicted what will be hot in specialty food for 2024.
  • Though a smaller segment than food, in many recent years beverage sales have grown at a faster pace, according to SFA's State of the Specialty Food Industry research , fueled by innovation.
  • These trends, and more, will be at the 2024 Winter Fancy Food Show in Las Vegas.
  • The largest B2B specialty food event in the western United States, the Winter Fancy Food Show features thousands of specialty food and beverage products from around the world.

LEO Pharma Presents Phase 3 Results of Delgocitinib Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE) at EADV 2023

Retrieved on: 
Friday, October 13, 2023
Health, Science, Pharmaceutical, Research, Clinical Trials, Janus, Congress, Journal of the European Academy of Dermatology and Venereology, DELTA, JAK, Week, LEO, IGA, CHE, Patient, Pharmaceutical industry, Silviculture, Dermatology, Venereology

DELTA 2 is the second of two pivotal phase 3 clinical trials with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).1,4

Key Points: 
  • DELTA 2 is the second of two pivotal phase 3 clinical trials with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).1,4
    DELTA 2 was a randomized, double-blind, cream vehicle-controlled trial.
  • Adults were randomized to either twice-daily delgocitinib cream (n=314) or cream vehicle (n=159) for 16 weeks followed by a separate 36-week extension trial.
  • “Through assessment of the DELTA 1 and DELTA 2 trial results, we aim to assess the efficacy and safety of delgocitinib cream in adults living with this hard-to-treat disease."
  • “This latest collection of clinical data for delgocitinib cream supports LEO Pharma’s unwavering commitment to addressing the critical unmet need in CHE,” says Kreesten Meldgaard Madsen, Chief Development Officer, LEO Pharma.

Harnessing IoT and AI: NG911 Market Set to Transform Public Safety Landscape

Retrieved on: 
Thursday, July 27, 2023
Cloud, Emergency, PSAP, Noise, Internet of things, Smart, Intelligence, CHE, IP, Machine learning, Growth, Artificial intelligence, City, Ecosystem, Catalysis, GIS, Mobile phone

NG911, the next-generation emergency response system, marks a paradigm shift in the public safety landscape, catering to the dynamic demands and technologies of citizens.

Key Points: 
  • NG911, the next-generation emergency response system, marks a paradigm shift in the public safety landscape, catering to the dynamic demands and technologies of citizens.
  • Unlike the legacy voice-centric E9-1-1 network, NG911 leverages internet protocol (IP)-based communications to empower first responders with enhanced speed, accuracy, and preparedness.
  • The Rise of IoT and Smart Cities: A Catalyst for NG911 Growth
    The emergence of IoT, smart cities, connected vehicles, and wearables offers new growth opportunities for NG911 systems.
  • Additionally, market share analysis for NG911 primary contract holders, NGCS providers, and CHE providers is included.

Top Trends for 2023 Summer Fancy Food Show Revealed by Specialty Food Association Trendspotter Panel

Retrieved on: 
Monday, July 17, 2023
Emerald, Taste, Travel, Honey, The Summer Show, Drink, Snack, CRC, Food industry, Heat, Specialty Food Association, Cirkus, Javits Center, UBE, Cheese, CHE, Vegetable, Fruit, Drexel University, Doctor of Philosophy, Attitude, Melati, Sur La Table, Creativity, Butter, FC Kramatorsk, Panel, Cooking, Tea, Fonio, Coffee, Sesame, SFA, Foresight, Health, CFS, Ruby, Spice, Food, Condiment, Environment, Tourism, Fast food, Convenience food, Soft drink, Bottled water, Flour, Salted duck egg

NEW YORK, July 17, 2023 /PRNewswire/ -- The Specialty Food Association Trendspotter Panel tasted its way through the sold-out 67th Summer Fancy Food Show in search of the products and flavors that will influence the specialty food industry in the months ahead.

Key Points: 
  • NEW YORK, July 17, 2023 /PRNewswire/ -- The Specialty Food Association Trendspotter Panel tasted its way through the sold-out 67th Summer Fancy Food Show in search of the products and flavors that will influence the specialty food industry in the months ahead.
  • In their Trends from the Summer Fancy Food Show report, the Panel identified Flavor Fluidity, Salty Snacks, One-Step Convenience, African Specialties, Asian-Inspired Snack Specialties, and Food with an Edgy Attitude as the top emerging trends.
  • Trends identified at the 2023 Summer Fancy Food Show will influence not only specialty but the food industry at large.
  • "The trends identified at the 2023 Summer Fancy Food Show will influence not only specialty, but the food industry at large, in the months ahead."